Could a booster shot shield transplant patients from shingles?
NCT ID NCT07443709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-suppressing medications. The trial will randomly assign 75 participants to receive either the booster or no booster, then measure antibody levels and track safety for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Shingrix (recombinant zoster vaccine) booster dose
What this could lead to
If it works, this could lead to a simple booster shot that helps prevent shingles in transplant patients, reducing severe complications and hospital visits.
What could go wrong
This is a small, early-phase pilot study (75 people) and may not prove the booster is effective or safe for all transplant patients. Immune responses can vary, and there is a risk of side effects or organ rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZOSTER; HERPES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lausanne University Hospital
Lausanne, Canton of Vaud, 1011, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••